Published on 22/02/2012
The European Commission has granted marketing authorisation for a new thyroid cancer pill called Caprelsa.
Thyroid cancer is one of the rarer types of cancer, accounting for only 1 per cent of all cancer cases in England. Each year in Wales there are an estimated 1,800 new cases of thyroid cancer, and most are diagnosed in people between the ages of 30 and 50.
AstraZeneca's thyroid cancer pill Caprelsa has been given European license for the treatment of aggressive and symptomatic medullary thyroid cancer (MTC), a rare type of the disease with a poor prognosis.
The new drug has been approved after a successful Phase III trial which involved 331 patients with advanced MTC that has progressed and spread to other parts of the body. Use of Caprelsa showed a 54% reduction in risk of disease progression compared to the placebo.
Caprelsa works as a once-daily oral treatment that blocks the blood supply to the tumour and reduces its growth.
This will be the first therapy approved in Europe to treat the disease.
However, it will take a while for the National Institute for Health and Clinical Excellence (NICE) to decide whether to approve the drug for use on the NHS.
In the meantime, patients with private medical insurance may have access to Caprelsa on their policy. Extended cancer cover often funds the use of licensed drugs not available on the NHS, so compare health insurance online now.
© ActiveQuote Ltd. 2012Categories: Medical